Seres Therapeutics (NASDAQ:MCRB) Stock Price Breaks Below 50 Day Moving Average – Here’s What Happened

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s share price crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $4.73 and traded as low as $3.35. Seres Therapeutics shares last traded at $3.48, with a volume of 71,192 shares traded.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Zacks Research upgraded shares of Seres Therapeutics to a “hold” rating in a research note on Tuesday, June 23rd. Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. Wall Street Zen upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, HC Wainwright began coverage on Seres Therapeutics in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Seres Therapeutics has a consensus rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Trading Down 12.5%

The business’s fifty day simple moving average is $4.69 and its two-hundred day simple moving average is $6.56. The stock has a market capitalization of $29.45 million, a P/E ratio of -1.21 and a beta of 0.21.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.18) by $2.65. Seres Therapeutics had a negative net margin of 1,192.94% and a negative return on equity of 114.82%. The company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.18 million. On average, equities research analysts anticipate that Seres Therapeutics, Inc. will post -6.33 earnings per share for the current year.

Hedge Funds Weigh In On Seres Therapeutics

A hedge fund recently bought a new stake in Seres Therapeutics stock. Integrated Wealth Concepts LLC acquired a new position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutics designed to treat diseases by restoring or modifying the human microbiome. The company’s research has centered on microbial communities that may influence immune function, gastrointestinal health and disease progression.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was developed to reduce the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.